Document is current
Any future updates will be listed below
-
Authors
Abedin, Sameem M. https://orcid.org/0000-0003-1165-4766
Guru Murthy, Guru Subramanian https://orcid.org/0000-0002-9889-2611
Hamadani, Mehdi https://orcid.org/0000-0001-5372-510X
Michaelis, Laura C. https://orcid.org/0000-0002-1798-9658
Carlson, Karen-Sue
Runaas, Lyndsey
Gauger, Katelyn
Desai, Avinash G.
Chen, Mary M.
Li, Kate L.
Rotibi, Mojisola
Syed, Umar
Vusirikala, Madhuri
Harrington, Alexandra
Atallah, Ehab L.
-
Funding
Funding for this research was provided by:
Actinium Pharmaceuticals
- License Information
-
More Information
Article History
Received: 31 October 2024
Revised: 10 January 2025
Accepted: 30 January 2025
First Online: 15 February 2025
Competing interests
: S.M.A. received consultancy fees from Incyte Inc, Servier, and Soba; and received research funding from Actinium, AltruBio, and Incyte. G.S.G.M. received consultancy and speaker bureau fees from Amgen; speaker bureau fees from Rigel; advisory board fees from Pfizer, BMS, Autolus, Syndax and Stemline; and research funding from LOXO/Lilly, Zentalis, Schrodinger, and Merck. M.H. received consultancy, research funding and speaker bureau fees from ADC Therapeutics; research funding from Spectrum Pharmaceuticals and Astellas Pharma; consultancy and speaker bureau fees from Kite Pharma; speaker bureau fees from Sanofi Genzyme, AstraZeneca and BeiGene; and consultancy fees from Omeros, BMS, Genmab, CRISPR, Allovir, Caribou, Autolus, Forte Biosciences, AbbVie, and Byondis. L.C.M. received consultancy fees from Disc Medicine. K.S.M., L.R., and K.G. have no conflicts of interest to disclose. A.G.D., M.M.C., K.L.L., M.R., U.S., and M.V. are currently employed by Actinium Pharmaceuticals and hold equity in this publicly traded company.
